Search by Drug Name, NDC or Jcode

    Internal Navigation

    HCPCS Details

    HCPC J0172
    Short Description Inj, aducanumab-avwa, 2 mg
    Long Description Injection, aducanumab-avwa, 2 mg
    Pricing indicator 00
    Coverage code D
    ASC payment group code YY
    BETOS2 code O1E
    Action code N
    Type of service 1
    Effective date 2022-04-07
    Date Added 2022-01-01

    HCPCS/NDC Cross-Walk

    NDC HCPC Description Drug Name Labeler Name HCPCS Dosage PKG Size PKG QTY Bill Units Bill Units PKG
    64406010101 J0172 Inj, aducanumab-avwa, 2 mg Aduhelm BIOGEN 2 MG 1.7 1 85 85
    64406010202 J0172 Inj, aducanumab-avwa, 2 mg Aduhelm BIOGEN 2 MG 3 1 150 150
    The ASP crosswalks are maintained by the Division of Data Analysis and Market Based Pricing to support ASP-based Medicare Part B payments only. The crosswalks are intended to help the public (including entities that submit manufacturer ASP data and providers who bill for drugs) understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes. The crosswalks are not intended to be a comprehensive list of all drugs/NDCs available in the United States. The NDC to HCPCS Crosswalk also includes information on the NDC package size and the number of billable units (as defined by the HCPCS code descriptor). Comments on the file may be sent to [email protected].

    HCPCS Billing Calculator

    Dosage given to patient (per dose)
    HCPCS Dosage 2 MG
    HCPCS/CPT Billing Units 0.5
    Total doses ordered
    Billing Units 0.5

    Drug Details

    • Aducanumab-avwa injection is used to reduce amyloid beta plaque, a protein found in the brain of people with Alzheimer's disease (a brain disease that slowly destroys the memory and ability to think, learn, communicate and handle daily activities). It is used to treat people with mild cognitive impairment (MCI) or mild dementia. Aducanumab-avwa injection is in a class of medications called monoclonal antibodies. It works by blocking the formation of amyloid beta in the brain.